Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition and application of furandiene-germacrone composition in preparation of psoriasis medicines

A technology of furadienes and compositions, applied in the field of pharmacy, can solve problems such as long course of disease, expensive side effects of drugs, troubles in normal life and daily work of patients, etc.

Pending Publication Date: 2022-01-14
HAINAN BIKAI PHARM CO LTD
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Due to the high incidence of psoriasis, and it is easy to relapse, the course of the disease is long, and the drugs for the treatment of psoriasis are relatively expensive or have relatively large side effects, so it brings a certain economic burden to the patient and causes physical and mental damage to the patient. It is a great pain, causing troubles to patients' normal life and daily work. Therefore, the research of new drugs with high efficiency and low toxicity for the treatment of psoriasis has important clinical significance

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition and application of furandiene-germacrone composition in preparation of psoriasis medicines
  • Composition and application of furandiene-germacrone composition in preparation of psoriasis medicines
  • Composition and application of furandiene-germacrone composition in preparation of psoriasis medicines

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Inhibitory Effect of Furandiene Gemaconone Composition on the Release of Nitric Oxide (NO) from Mouse Mononuclear Macrophages (RAW264.7) Induced by Lipopolysaccharide (LPS)

[0026] 1. Source of materials

[0027] 1. Cell line:

[0028] The RAW264.7 cell line was purchased from Wuhan Punuosai Life Technology Co., Ltd.;

[0029] 2. Main reagents:

[0030] Furanadiene and gemaerone were provided by Hainan Bikai Drug Research Institute; Phosphate BufferedSaline (PBS) buffer, trypsin and penicillin-streptomycin solution were purchased from Gibco Company; RAW264.7 cell special medium and fetal calf Serum was purchased from Wuhan Punuosai Life Technology Co., Ltd.; lipopolysaccharide (LPS) was purchased from Shanghai Yuanye Biotechnology Co., Ltd.; CCK-8 kit was purchased from Glpbio; nitric oxide (NO) detection kit was purchased from Biyuntian Biotechnology Co., Ltd;

[0031] 2. Experimental method

[0032] 1. Cell culture

[0033] RAW264.7 cells were grown in RAW264.7...

Embodiment 2

[0050] Example 2 Inhibitory effect of the furadiened gemaerone composition on the viability of human immortalized epidermal cell lines (HaCaT)

[0051] 1. Source of materials

[0052] 1. Cell line:

[0053] Immortalized human epidermal cell line (HaCaT) was purchased from Wuhan Punosai Life Technology Co., Ltd.

[0054] 2. Main reagents:

[0055] Furanadiene and Gemaerone were provided by Effective Company of Hainan Bikai Pharmaceutical Research Institute; Phosphate BufferedSaline (PBS) buffer solution, Dulbecco's Modified Eagle Medium (DMEM) medium, trypsin and penicillin-streptomycin solution were purchased from Gibco Company; The CCK-8 kit was purchased from Glpbio;

[0056] 2. Experimental method

[0057] 1. Cell culture

[0058] HaCaT cells were grown in DMED medium containing 15% fetal bovine serum, 100 U / ml penicillin and 100 mg / l streptomycin at 37°C, 5% CO 2 cultured in an incubator. The cells were passaged and digested with 0.25% trypsin containing 0.02% EDTA, a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a composition. The composition is composed of furandiene and germacrone. The invention also discloses an application of the furandiene-germacrone composition in preparation of medicines for treating psoriasis. The composition has a remarkable inhibition effect on content of NO released by LPS-induced RAW264.7 cells. The composition has remarkable effect of inhibiting proliferation of HaCaT cells. In-vitro tests prove that furandiene and germacrone have a remarkable curative effect on psoriasis and can be used for preparing medicines for treating psoriasis.

Description

technical field [0001] The invention belongs to the technical field of pharmacy, and in particular relates to a composition and the application of a furadien-gemacone composition in the preparation of psoriasis medicines. Background technique [0002] Psoriasis, commonly known as psoriasis, is a chronic inflammatory skin disease. The disease mainly occurs in young and middle-aged people, and has a great impact on the physical health and mental status of patients. The clinical manifestations are mainly erythema and scales, and the disease can occur all over the body. The scalp and the extensor sides of the limbs are more common, and it usually aggravates in winter. [0003] There is currently no effective treatment for this disease, but it is not incurable. Appropriate symptomatic treatment can control symptoms. Because the disease is a chronic relapsing disease, many patients need long-term treatment, and various therapies have certain adverse reactions. There are combin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/343A61K31/122A61P17/06
CPCA61K31/343A61K31/122A61K9/0014A61P17/06A61K2300/00
Inventor 徐扬毛庆秋陈容徐朗方方
Owner HAINAN BIKAI PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com